BioAge Labs (BIOA) Stock Price, News & Analysis

Company Overview

BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions. The company is led by co-founder and Chief Executive Officer Kristen Fortney, Ph.D., whose background includes computational biology and aging research.

Key Stats

• Today's Range: $5.54 to $5.90
• 50-Day Range: $4.84 to $9.73
• 52-Week Range: $4.81 to $25.95
• Volume: 490,740 shs
• Average Volume: 799,237 shs
• Market Capitalization: $265.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Moderate Buy

BioAge Labs Stock Analysis - MarketRank™

BioAge Labs scored higher than 52% of companies evaluated by MarketBeat, and ranked 395th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioAge Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

BioAge Labs has a consensus price target of $33.00, representing about 470.9% upside from its current price of $5.78.

Amount of Analyst Coverage

BioAge Labs has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioAge Labs are expected to grow in the coming year, from ($2.56) to ($2.45) per share.

Price to Book Value per Share Ratio

BioAge Labs has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.84% of the float of BioAge Labs has been sold short.

Short Interest Ratio / Days to Cover

BioAge Labs has a short interest ratio ("days to cover") of 4.34.

Change versus previous month

Short interest in BioAge Labs has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAge Labs does not currently pay a dividend.

Dividend Growth

BioAge Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.49

News Sentiment

BioAge Labs has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for BioAge Labs this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added BioAge Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAge Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.55% of the stock of BioAge Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BioAge Labs has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/10/2026
• 3rd Annual Guggenheim Healthcare Innovation Conference: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BIOA
• Previous Symbol: NYSE:BIOA
• CIK: 1709941
• Web: bioagelabs.com
• Phone: (510) 806-1445
• Fax: N/A
• Employees: 62
• Year Founded: 2015

Price Target and Rating

• Average Price Target for BioAge Labs: $33.00
• High Price Target: $60.00
• Low Price Target: $8.00
• Potential Upside/Downside: +470.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.61 million
• Net Margins: -1,253.60%
• Pretax Margin: -1,253.60%
• Return on Equity: -31.42%
• Return on Assets: -29.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.51
• Quick Ratio: 15.51

Sales & Book Value

• Annual Sales: $8.99 million
• Price / Sales: 29.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.54 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 45,960,000
• Free Float: 37,842,000
• Market Cap: $265.65 million
• Optionable: Optionable
• Beta: 1.19